1446 related articles for article (PubMed ID: 26688484)
21. [The efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia].
Huang YT; Liu XF; Chen YF; Fu RF; Liu W; Zhang L; Yang RC
Zhonghua Xue Ye Xue Za Zhi; 2018 Jan; 39(1):32-36. PubMed ID: 29551030
[No Abstract] [Full Text] [Related]
22. A multicentre double-blind, double-dummy, randomised study of recombinant human thrombopoietin versus eltrombopag in the treatment of immune thrombocytopenia in Chinese adult patients.
Mei H; Xu M; Yuan G; Zhu F; Guo J; Huang R; Qin J; Lv T; Qin F; Cai H; Yin P; Qin T; Hu Y
Br J Haematol; 2021 Dec; 195(5):781-789. PubMed ID: 34528239
[TBL] [Abstract][Full Text] [Related]
23. A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.
Tomiyama Y; Miyakawa Y; Okamoto S; Katsutani S; Kimura A; Okoshi Y; Ninomiya H; Kosugi H; Nomura S; Ozaki K; Ikeda Y; Hattori T; Katsura K; Kanakura Y
J Thromb Haemost; 2012 May; 10(5):799-806. PubMed ID: 22409309
[TBL] [Abstract][Full Text] [Related]
24. Safety and Efficacy of Eltrombopag in Children and Adults with Immune Thrombocytopenia: A Systematic Review and Meta-Analysis.
Kolanis S; Vasileiou E; Hatzipantelis E; Economou M; Tragiannidis A
Cardiovasc Hematol Agents Med Chem; 2021; 19(1):83-92. PubMed ID: 32914722
[TBL] [Abstract][Full Text] [Related]
25. Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.
Tarantino MD; Fogarty PF; Shah P; Brainsky A
Platelets; 2015; 26(1):93-6. PubMed ID: 24433306
[TBL] [Abstract][Full Text] [Related]
26. Population Pharmacokinetic and Pharmacodynamic Modeling and Effects on Platelet Counts of Different Dosages of Eltrombopag in Chinese Patients With Chronic Primary Immune Thrombocytopenia.
Wu K; Thapar M; Farrell C; Hayes S; Guo H; Hou M; Zhang J
Clin Ther; 2015 Jul; 37(7):1382-95. PubMed ID: 25929594
[TBL] [Abstract][Full Text] [Related]
27. Dexamethasone plus oseltamivir versus dexamethasone in treatment-naive primary immune thrombocytopenia: a multicentre, randomised, open-label, phase 2 trial.
Sun L; Wang J; Shao L; Yuan C; Zhao H; Li D; Wang Z; Han P; Yu Y; Xu M; Zhao H; Qiu J; Zhou H; Liu X; Hou Y; Peng J; Hou M
Lancet Haematol; 2021 Apr; 8(4):e289-e298. PubMed ID: 33770484
[TBL] [Abstract][Full Text] [Related]
28. Changes in health-related quality of life with long-term eltrombopag treatment in adults with persistent/chronic immune thrombocytopenia: Findings from the EXTEND study.
Khelif A; Saleh MN; Salama A; Portella MDSO; Duh MS; Ivanova J; Grotzinger K; Roy AN; Bussel JB
Am J Hematol; 2019 Feb; 94(2):200-208. PubMed ID: 30417939
[TBL] [Abstract][Full Text] [Related]
29. The Cost-effectiveness of Eltrombopag for the Treatment of Immune Thrombocytopenia in the United States.
Tremblay G; Dolph M; Roy AN; Said Q; Forsythe A
Clin Ther; 2020 May; 42(5):860-872.e8. PubMed ID: 32199608
[TBL] [Abstract][Full Text] [Related]
30. Thrombopoietin Receptor Agonists in the Treatment of Chronic Resistant Primary Immune Thrombocytopenia: Efficacy and Safety Data in Real Clinical Practice.
Ptushkin VV; Vinogradova OY; Pankrashkina MM; Chernikov MV; Arshanskaya EG; Tkachenko NE
Ter Arkh; 2018 Aug; 90(7):70-76. PubMed ID: 30701925
[TBL] [Abstract][Full Text] [Related]
31. Efficacy of eltrombopag in management of bleeding symptoms associated with chronic immune thrombocytopenia.
Tarantino MD; Fogarty P; Mayer B; Vasey SY; Brainsky A
Blood Coagul Fibrinolysis; 2013 Apr; 24(3):284-96. PubMed ID: 23492914
[TBL] [Abstract][Full Text] [Related]
32. Eltrombopag for the treatment of chronic idiopathic (immune) thrombocytopenic purpura (ITP).
Boyers D; Jia X; Crowther M; Jenkinson D; Fraser C; Mowatt G
Health Technol Assess; 2011 May; 15 Suppl 1():23-32. PubMed ID: 21609650
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of eltrombopag in Chinese patients with chronic immune thrombocytopenia: stage 2 results from a multicenter phase III study.
Liu X; Hou M; Li J; Jin J; Huang M; Yu Z; Xu X; Zhang X; Yang R
Platelets; 2022 Jan; 33(1):82-88. PubMed ID: 33251910
[TBL] [Abstract][Full Text] [Related]
34. Thrombopoietin-receptor agonists for children with immune thrombocytopenia: a systematic review.
Zhang J; Liang Y; Ai Y; Xie J; Li Y; Zheng W
Expert Opin Pharmacother; 2017 Oct; 18(15):1543-1551. PubMed ID: 28845713
[TBL] [Abstract][Full Text] [Related]
35. Eltrombopag for the treatment of chronic immune (idiopathic) thrombocytopenic purpura.
Dmytrijuk A; Robie-Suh K; Rieves D; Pazdur R
Oncology (Williston Park); 2009 Nov; 23(13):1171-7. PubMed ID: 20043468
[TBL] [Abstract][Full Text] [Related]
36. Health-related quality of life in children with chronic immune thrombocytopenia treated with eltrombopag in the PETIT study.
Grainger JD; Blanchette VS; Grotzinger KM; Roy A; Bussel JB
Br J Haematol; 2019 Apr; 185(1):102-106. PubMed ID: 30592022
[TBL] [Abstract][Full Text] [Related]
37. Safety and efficacy of long-term treatment of chronic/persistent ITP with eltrombopag: final results of the EXTEND study.
Wong RSM; Saleh MN; Khelif A; Salama A; Portella MSO; Burgess P; Bussel JB
Blood; 2017 Dec; 130(23):2527-2536. PubMed ID: 29042367
[TBL] [Abstract][Full Text] [Related]
38. A randomized, double-blind, placebo-controlled, dose ranging study to assess the efficacy and safety of eltrombopag in patients receiving carboplatin/paclitaxel for advanced solid tumors.
Kellum A; Jagiello-Gruszfeld A; Bondarenko IN; Patwardhan R; Messam C; Mostafa Kamel Y
Curr Med Res Opin; 2010 Oct; 26(10):2339-46. PubMed ID: 20735290
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of the neonatal Fc receptor inhibitor efgartigimod in adults with primary immune thrombocytopenia (ADVANCE IV): a multicentre, randomised, placebo-controlled, phase 3 trial.
Broome CM; McDonald V; Miyakawa Y; Carpenedo M; Kuter DJ; Al-Samkari H; Bussel JB; Godar M; Ayguasanosa J; De Beuf K; Rodeghiero F; Michel M; Newland A;
Lancet; 2023 Nov; 402(10413):1648-1659. PubMed ID: 37778358
[TBL] [Abstract][Full Text] [Related]
40. Investigation of the efficacy and safety of eltrombopag to correct thrombocytopenia in moderate to severe dengue patients - a phase II randomized controlled clinical trial.
Chakraborty S; Alam S; Sayem M; Sanyal M; Das T; Saha P; Sayem M; Byapari BK; Tabassum CT; Kabir A; Amin MR; Nabi AHMN
EClinicalMedicine; 2020 Dec; 29-30():100624. PubMed ID: 33294822
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
